DOCSLIB.ORG

Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment cancers Review Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment Pankaj Ahluwalia 1, Meenakshi Ahluwalia 2, Ashis K. Mondal 1 , Nikhil S. Sahajpal 1, Vamsi Kota 3 , Mumtaz V. Rojiani 4 and Ravindra Kolhe 1,* 1 Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; [email protected] (P.A.); [email protected] (A.K.M.); [email protected] (N.S.S.) 2 Department of Neurosurgery, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; [email protected] 3 Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; [email protected] 4 Department of Pharmacology, Penn State University College of Medicine, Hershey, PA 17033, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-706-721-2771; Fax: +1-706-434-6053 Simple Summary: Cancer is one of the leading causes of mortality around the globe. In the past decades, there has been rapid progress in the development of tools to detect, screen, and treat several cancers. For its benefit to reach a wider patient population, significant challenges such as tumor Citation: Ahluwalia, P.; Ahluwalia, heterogeneity, resistance to therapies, and lack of biomarkers should be addressed. The immune M.; Mondal, A.K.; Sahajpal, N.S.; system holds the key to a greater understanding of these complex barriers. Natural Killer cells are Kota, V.; Rojiani, M.V.; Kolhe, R. cytotoxic cells of innate immunity that can kill multiple tumorigenic cells. Dendritic cells link innate Natural Killer Cells and Dendritic and adaptive immunity by processing and presenting tumor-derived antigens to initiate anti-tumor Cells: Expanding Clinical Relevance T cell response. These immune cells and associated gene signatures have emerged as potential in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment. biomarkers with prognostic and predictive potential in several cancers. In this review article, we have Cancers 2021, 13, 4037. https:// discussed the biological roles of NK cells and DCs along with their translational relevance in NSCLC. doi.org/10.3390/cancers13164037 Abstract: Non-small cell lung cancer (NSCLC) is a major subtype of lung cancer that accounts for Academic Editors: David Entenberg, almost 85% of lung cancer cases worldwide. Although recent advances in chemotherapy, radiother- Panagiota Filippou and apy, and immunotherapy have helped in the clinical management of these patients, the survival rate George Karagiannis in advanced stages remains dismal. Furthermore, there is a critical lack of accurate prognostic and stratification markers for emerging immunotherapies. To harness immune response modalities for Received: 14 July 2021 therapeutic benefits, a detailed understanding of the immune cells in the complex tumor microenvi- Accepted: 5 August 2021 ronment (TME) is required. Among the diverse immune cells, natural killer (NK cells) and dendritic Published: 11 August 2021 cells (DCs) have generated tremendous interest in the scientific community. NK cells play a critical role in tumor immunosurveillance by directly killing malignant cells. DCs link innate and adaptive Publisher’s Note: MDPI stays neutral immune systems by cross-presenting the antigens to T cells. The presence of an immunosuppressive with regard to jurisdictional claims in milieu in tumors can lead to inactivation and poor functioning of NK cells and DCs, which results published maps and institutional affil- iations. in an adverse outcome for many cancer patients, including those with NSCLC. Recently, clinical intervention using modified NK cells and DCs have shown encouraging response in advanced NSCLC patients. Herein, we will discuss prognostic and predictive aspects of NK cells and DC cells with an emphasis on NSCLC. Additionally, the discussion will extend to potential strategies that seek to enhance the anti-tumor functionality of NK cells and DCs. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article Keywords: NK cells; natural killer cells; DCs; dendritic cells; immunotherapy; prognostic; predictive; distributed under the terms and cancer; gene expression; lung cancer; therapeutics; NSCLC conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Cancers 2021, 13, 4037. https://doi.org/10.3390/cancers13164037 https://www.mdpi.com/journal/cancers Cancers 2021, 13, 4037 2 of 18 1. Introduction Lung carcinoma is one of the deadliest cancers globally, with almost 1.8 million deaths annually [1]. Lung cancer consists of heterogenous subtypes that can be differentiated at epidemiological, histological, and molecular levels. Small-cell lung cancer (SCLC) accounts for 13%, while non-small cell lung cancer (NSCLC) causes 76% of lung cancer cases [2]. Tobacco smoking has a well-documented association, with a high prevalence of lung carcinoma. Furthermore, air pollution (household and outdoor) is the second most leading risk factor of lung cancer [3]. According to one estimate, more than 91% of the global population lives under WHO air quality guideline levels [4]. Air pollution consists of fine particulate matter (PM10 and PM2.5), gases (oxides of sulfur and carbon), and metals (lead, nickel, and vanadium). According to one meta-analysis, an increase in every 10 µg/m3 of PM10 levels leads to a 22% higher risk of lung cancer [5]. The incidence and mortality of lung cancer are falling in the United States due to strengthened tobacco control and public education, but are rising in developing countries [6]. In the United States, from 2008 to 2016, NSCLC related incidence decreased at an annual rate of 3.1%. The specific survival in lung cancer patients improved from 26% in 2001 to 35% in 2014 [2]. The advances in treatment regimens including the incorporation of targeted therapies and immunotherapies are major factors in this improvement. Surgical resection of the tumor is most effective for stage I, stage II, and some stage III NSCLC cases [7]. Unfortunately, most of the patients have tumor recurrence with a 5-year survival rate that falls from 83% in stage IA to 36% for stage IIIA patients [8]. Platinum compounds have been used against cancer since the 1978 approval by the FDA [9]. Platinum drugs cause damage to tumor cells by cross-linking DNA. In healthy cells, efficient DNA damage response can repair the damage, but due to changes accumulated through the process of cancer evolution, most of the cancer cells lack DNA repair pathways and are subsequently killed [10]. Platinum-based doublet therapies (cisplatin combined with docetaxel or other cytotoxic compounds) have been standard of care for advanced NSCLC patients with a good performance status [11]. Besides these, platinum triplets (addition of a third component—bevacizumab, an anti-VEGF moAb) are recommended for advanced metastatic NSCLC [12,13]. For NSCLC patients with activating EGFR mutations (30–50% of Asians and 15% Caucasians), tyrosine kinase inhibitors (TKIs) comprise the first-line therapeutic strategy [14]. Encouragingly, recent breakthroughs in immunotherapies have provided a new direction to the management of lung cancer patients. Currently, patients with higher expression of PD-L1 are administered pembrolizumab (anti-PD-1) as a first- and second-line therapy in patients with advanced NSCLC [15]. Atezolizumab (anti-PD-L1) and Nivolumab (anti-PD-1) are approved as a second-line therapy, while Durvalumab (anti-PD-L1) is used as a maintenance therapy in unresectable stage III NSCLC patients [15–17]. The tumor microenvironment is composed of malignant cells along with fibroblasts, extracellular matrix (ECM), endothelial cells, adipocytes, and immune cells [18] (Figure1). Tumors can be divided into two major immunological subtypes: hot (high T cell activity) and cold (lack of T cell priming/activation) based on inflammatory cytokine profile [19]. In the cancer progression cycle, excessive secretion of PD-L1 in the tumor and enhanced PD-1 signaling inactivates T cells leading to tumor growth and metastasis [20]. The use of novel immunotherapeutic agents, such as nivolumab (anti-PD-1), pembrolizumab (anti- PD-1), and atezolizumab (anti PD-L1), has led to the improved overall survival of NSCLC patients compared to treatment with docetaxel [16,21,22]. Further, the combination of cyto- toxic therapy and immunotherapy has shown synergistic improvements in the anti-tumor response. The combination of pemetrexed (folate antimetabolites), carboplatin (platinum- based antineoplastic drug), and pembrolizumab (anti-PD-1) led to the improvement of the objective response rate and progression-free survival [23,24]. This striking difference was exhibited in the benefits of immunotherapy, as hot tumors show a higher response rate to immunotherapy. The immune checkpoint blockade (ICB) is effective in patients with expression of PD-L1 or high TMB (tumor mutation burden), but there are different approaches required to target cold tumors. TMB is the number of nonsynonymous coding Cancers 2021, 13, x 3 of 18 Cancers 2021, 13, 4037 3 of 18 of nonsynonymous coding mutations per million bases (Mb) and is a predictive biomarker mutationsfor ICB therapy per million efficacy. bases It is (Mb)associated and is with a predictive increased biomarker secretion of for neoantigens ICB therapy and efficacy. cyto- It istoxic associated T cell activity with increased in several secretion cancers
Load more

Recommended publications
  • NK Cell Memory to Cytomegalovirus: Implications for Vaccine Development
    Review NK Cell Memory to Cytomegalovirus: Implications for Vaccine Development Calum Forrest 1 , Ariane Gomes 1 , Matthew Reeves 1,* and Victoria Male 2,* 1 Institute of Immunity & Transplantation, UCL, Royal Free Campus, London NW3 2PF, UK; [email protected] (C.F.); [email protected] (A.G.) 2 Department of Metabolism, Digestion and Reproduction, Imperial College London, Chelsea and Westminster Campus, London SW10 9NH, UK * Correspondence: [email protected] (M.R.); [email protected] (V.M.) Received: 24 June 2020; Accepted: 15 July 2020; Published: 20 July 2020 Abstract: Natural killer (NK) cells are innate lymphoid cells that recognize and eliminate virally-infected and cancerous cells. Members of the innate immune system are not usually considered to mediate immune memory, but over the past decade evidence has emerged that NK cells can do this in several contexts. Of these, the best understood and most widely accepted is the response to cytomegaloviruses, with strong evidence for memory to murine cytomegalovirus (MCMV) and several lines of evidence suggesting that the same is likely to be true of human cytomegalovirus (HCMV). The importance of NK cells in the context of HCMV infection is underscored by the armory of NK immune evasion genes encoded by HCMV aimed at subverting the NK cell immune response. As such, ongoing studies that have utilized HCMV to investigate NK cell diversity and function have proven instructive. Here, we discuss our current understanding of NK cell memory to viral infection with a focus on the response to cytomegaloviruses. We will then discuss the implications that this will have for the development of a vaccine against HCMV with particular emphasis on how a strategy that can harness the innate immune system and NK cells could be crucial for the development of a vaccine against this high-priority pathogen.
    [Show full text]
  • Single-Cell Profiling Identifies Impaired Adaptive NK Cells Expanded After HCMV Reactivation in Haploidentical HSCT
    Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT Elisa Zaghi, … , Enrico Lugli, Domenico Mavilio JCI Insight. 2021;6(12):e146973. https://doi.org/10.1172/jci.insight.146973. Research Article Hematology Immunology Graphical abstract Find the latest version: https://jci.me/146973/pdf RESEARCH ARTICLE Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT Elisa Zaghi,1 Michela Calvi,1,2 Simone Puccio,3 Gianmarco Spata,1 Sara Terzoli,1 Clelia Peano,4 Alessandra Roberto,3 Federica De Paoli,3 Jasper J.P. van Beek,3 Jacopo Mariotti,5 Chiara De Philippis,5 Barbara Sarina,5 Rossana Mineri,6 Stefania Bramanti,5 Armando Santoro,5 Vu Thuy Khanh Le-Trilling,7 Mirko Trilling,7 Emanuela Marcenaro,8 Luca Castagna,5 Clara Di Vito,1,2 Enrico Lugli,3,9 and Domenico Mavilio1,2 1Unit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. 2BIOMETRA, Università degli Studi di Milano, Milan, Italy. 3Laboratory of Translational Immunology, 4Institute of Genetic and Biomedical Research, UoS Milan, National Research Council, and Genomic Unit, 5Bone Marrow Transplant Unit, and 6Molecular Biology Section, Clinical Investigation Laboratory, IRCCS Humanitas Research Hospital, Milan, Italy. 7Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 8Department of Experimental Medicine, University of Genoa, Genoa, Italy. 9Flow Cytometry Core, IRCCS Humanitas Research Hospital, Milan, Italy. Haploidentical hematopoietic stem cell transplantation (h-HSCT) represents an efficient curative approach for patients affected by hematologic malignancies in which the reduced intensity conditioning induces a state of immunologic tolerance between donor and recipient.
    [Show full text]
  • Natural Killer Cells in Antiviral Immunity
    REVIEWS Natural killer cells in antiviral immunity Niklas K. Björkström ✉ , Benedikt Strunz and Hans- Gustaf Ljunggren Abstract | Natural killer (NK) cells play an important role in innate immune responses to viral infections. Here, we review recent insights into the role of NK cells in viral infections, with particular emphasis on human studies. We first discuss NK cells in the context of acute viral infections, with flavivirus and influenza virus infections as examples. Questions related to activation of NK cells, homing to infected tissues and the role of tissue- resident NK cells in acute viral infections are also addressed. Next, we discuss NK cells in the context of chronic viral infections with hepatitis C virus and HIV-1. Also covered is the role of adaptive- like NK cell expansions as well as the appearance of CD56− NK cells in the course of chronic infection. Specific emphasis is then placed in viral infections in patients with primary immunodeficiencies affecting NK cells. Not least, studies in this area have revealed an important role for NK cells in controlling several herpesvirus infections. Finally, we address new data with respect to the activation of NK cells and NK cell function in humans infected with severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) giving rise to coronavirus disease 2019 (COVID-19). Antibody- dependent Almost 50 years ago, a small number of research groups In humans, mature NK cells are traditionally identified cellular cytotoxicity started to observe unexpected spontaneous cytotoxic as CD3−CD56+ lymphocytes. They were long thought to (ADCC). A mechanism by which activities among lymphocytes.
    [Show full text]
  • KIR Polymorphism Modulates the Size of the Adaptive NK Cell Pool in Human C Ytomegalovirus−Infected Individuals
    KIR Polymorphism Modulates the Size of the Adaptive NK Cell Pool in Human C ytomegalovirus−Infected Individuals This information is current as Angela R. Manser, Nadine Scherenschlich, Christine Thöns, of September 26, 2021. Hartmut Hengel, Jörg Timm and Markus Uhrberg J Immunol published online 13 September 2019 http://www.jimmunol.org/content/early/2019/09/12/jimmun ol.1900423 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2019/09/12/jimmunol.190042 Material 3.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published September 13, 2019, doi:10.4049/jimmunol.1900423 The Journal of Immunology KIR Polymorphism Modulates the Size of the Adaptive NK Cell Pool in Human Cytomegalovirus–Infected Individuals Angela R. Manser,* Nadine Scherenschlich,* Christine Tho¨ns,† Hartmut Hengel,‡,x Jo¨rg Timm,† and Markus Uhrberg* Acute infection with human CMV (HCMV) induces the development of adaptive NKG2C+ NK cells.
    [Show full text]
  • A New Hope for Cd56negcd16pos NK Cells As Unconventional Cytotoxic Mediators: an Adaptation to Chronic Diseases
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2020 A New Hope for CD56negCD16pos NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases Forconi, Catherine S ; Oduor, Cliff I ; Oluoch, Peter O ; Ong’echa, John M ; Münz, Christian ;Bailey, Jeffrey A ; Moormann, Ann M Abstract: Natural Killer (NK) cells play an essential role in antiviral and anti-tumoral immune responses. In peripheral blood, NK cells are commonly classified into two major subsets: CD56brightCD16neg and CD56dimCD16pos despite the characterization of a CD56negCD16pos subset 25 years ago. Since then, several studies have described the prevalence of an CD56negCD16pos NK cell subset in viral non- controllers as the basis for their NK cell dysfunction. However, the mechanistic basis for their cytotoxic impairment is unclear. Recently, using a strict flow cytometry gating strategy to exclude monocytes, we reported an accumulation of CD56negCD16pos NK cells in Plasmodium falciparum malaria-exposed children and pediatric cancer patients diagnosed with endemic Burkitt lymphoma (eBL). Here, we use live-sorted cells, histological staining, bulk RNA-sequencing and flow cytometry to confirm that this CD56negCD16pos NK cell subset has the same morphological features as the other NK cell subsets and a similar transcriptional profile compared to CD56dimCD16pos NK cells with only 120 genes differentially expressed (fold change of 1.5, p < 0.01 and FDR<0.05) out of 9235 transcripts. CD56negCD16pos NK cells have a distinct profile with significantly higher expression of MPEG1 (perforin 2), FCGR3B (CD16b), FCGR2A, and FCGR2B (CD32A and B) as well as CD6, CD84, HLA-DR, LILRB1/2, and PDCD1 (PD-1), whereas Interleukin 18 (IL18) receptor genes (IL18RAP and IL18R1), cytotoxic genes such as KLRF1 (NKp80) and NCR1 (NKp46), and inhibitory HAVCR2 (TIM-3) are significantly down-regulated compared to CD56dimCD16pos NK cells.
    [Show full text]
  • High-Dimensional Analysis Reveals a Distinct Population of Adaptive-Like Tissue
    bioRxiv preprint doi: https://doi.org/10.1101/2019.12.20.883785; this version posted December 20, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 High-dimensional analysis reveals a distinct population of adaptive-like tissue- 2 resident NK cells in human lung 3 4 Nicole Marquardt1*, Marlena Scharenberg1, Jeffrey E. Mold2, Joanna Hård2, Eliisa 5 Kekäläinen3,4, Marcus Buggert1, Son Nguyen5,6, Jennifer N. Wilson1, Mamdoh Al- 6 Ameri7, Hans-Gustaf Ljunggren1, Jakob Michaëlsson1 7 8 Running title: Adaptive-like human lung tissue-resident NK cells 9 10 Affiliations: 11 1Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, 12 Stockholm, Sweden 13 2Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden 14 3Translational Immunology Research Program & Department of Bacteriology and 15 Immunology, University of Helsinki, Finland 16 4HUSLAB, Division of Clinical Microbiology, Helsinki University Hospital, Helsinki, 17 Finland, 18 5Department of Microbiology, Perelman School of Medicine, University of 19 Pennsylvania, Philadelphia, PA, USA 20 6Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, 21 Philadelphia, PA, USA 22 7Thoracic Surgery, Department of Molecular Medicine and Surgery, Karolinska 23 Institutet, Karolinska University Hospital, Stockholm, Sweden 24 1 bioRxiv preprint doi: https://doi.org/10.1101/2019.12.20.883785; this version posted December 20, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells Lisa L
    Published OnlineFirst June 21, 2017; DOI: 10.1158/2326-6066.CIR-16-0296 Research Article Cancer Immunology Research Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells Lisa L. Liu1, Vivien Beziat 2,3, Vincent Y.S. Oei4,5, Aline Pfefferle1, Marie Schaffer1, Soren€ Lehmann6,7, Eva Hellstrom-Lindberg€ 7, Stefan Soderh€ all€ 8, Mats Heyman8, Dan Grander 9, and Karl-Johan Malmberg1,4,5 Abstract Manipulation of human natural killer (NK) cell repertoires eactivity against HLA-mismatched targets. The ex vivo expanded promises more effective strategies for NK cell–based cancer adaptive NK cells gradually obtained a more differentiated immunotherapy. A subset of highly differentiated NK cells, phenotype and were specificandhighlyefficient killers of termed adaptive NK cells, expands naturally in vivo in response allogeneic pediatric T- and precursor B-cell acute lymphoblastic to human cytomegalovirus (HCMV) infection, carries unique leukemia (ALL) blasts, previously shown to be refractory to repertoires of inhibitory killer cell immunoglobulin-like recep- killing by autologous NK cells and the NK-cell line NK92 tors (KIR), and displays strong cytotoxicity against tumor cells. currently in clinical testing. Selective expansion of NK cells Here, we established a robust and scalable protocol for ex vivo that express one single inhibitory KIR for self-HLA class I would generation and expansion of adaptive NK cells for cell therapy allow exploitation of the full potential of NK-cell alloreactivity against pediatric acute lymphoblastic leukemia (ALL). Culture in cancer immunotherapy. In summary, our data suggest that of polyclonal NK cells together with feeder cells expressing adaptive NK cells may hold utility for therapy of refractory ALL, HLA-E, the ligand for the activating NKG2C receptor, led to either as a bridge to transplant or for patients that lack stem cell selective expansion of adaptive NK cells with enhanced allor- donors.
    [Show full text]
  • SIV-Induced Terminally Differentiated Adaptive NK Cells in Lymph Nodes Associated with Enhanced MHC-E Restricted Activity
    ARTICLE https://doi.org/10.1038/s41467-021-21402-1 OPEN SIV-induced terminally differentiated adaptive NK cells in lymph nodes associated with enhanced MHC-E restricted activity Nicolas Huot 1, Philippe Rascle1,2, Caroline Petitdemange1, Vanessa Contreras3, Christina M. Stürzel4, Eduard Baquero5, Justin L. Harper 6, Caroline Passaes 1, Rachel Legendre 7, Hugo Varet 8, Yoann Madec 9, Ulrike Sauermann 10, Christiane Stahl-Hennig10, Jacob Nattermann11, Asier Saez-Cirion 1, Roger Le Grand3, R. Keith Reeves 12, Mirko Paiardini 6,13, Frank Kirchhoff 4, Beatrice Jacquelin 1 & ✉ Michaela Müller-Trutwin 1 1234567890():,; Natural killer (NK) cells play a critical understudied role during HIV infection in tissues. In a natural host of SIV, the African green monkey (AGM), NK cells mediate a strong control of SIVagm infection in secondary lymphoid tissues. We demonstrate that SIVagm infection induces the expansion of terminally differentiated NKG2alow NK cells in secondary lymphoid organs displaying an adaptive transcriptional profile and increased MHC-E-restricted cytotoxicity in response to SIV Env peptides while expressing little IFN-γ. Such NK cell differentiation was lacking in SIVmac-infected macaques. Adaptive NK cells displayed no increased NKG2C expression. This study reveals a previously unknown profile of NK cell adaptation to a viral infection, thus accelerating strategies toward NK-cell directed therapies and viral control in tissues. 1 Institut Pasteur, Unité HIV, Inflammation et Persistance, Paris, France. 2 Université Paris Diderot, Sorbonne Paris Cité, Paris, France. 3 CEA-Université Paris Sud-Inserm, U1184, IDMIT Department, IBFJ, Fontenay-aux-Roses, France. 4 Ulm University Medical Center, Ulm, Germany. 5 Institut Pasteur, Unité de Virologie Structurale, Paris, France.
    [Show full text]
  • Human Antigen-Specific Memory Natural Killer Cell Responses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.09.374348; this version posted November 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Human antigen-specific memory natural killer cell responses develop 2 against HIV-1 and influenza virus and are dependent on MHC-E 3 restriction 4 5 6 Stephanie Jost1, Olivier Lucar1, Taylor Yoder1, Kyle Kroll1, Sho Sugawara1, Scott Smith1, Rhianna 7 Jones1, George Tweet1, Alexandra Werner1, Phillip J. Tomezsko2, Haley L. Dugan2†, Joshua 1 3 3 4 5 8 Ghofrani , Marcus Altfeld , Adam Grundhoff , Michaela Muller-Trutwin , Paul Goepfert , R. Keith 9 Reeves1,2 * 10 11 1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard 12 Medical School, Boston, MA 02115, USA; 2Ragon Institute of Massachusetts General Hospital, 13 MIT, and Harvard, Cambridge, MA 02139, USA; 3Heinrich Pette Institute, Leibniz Institute for 14 Experimental Virology, 20251 Hamburg, Germany; 4Institut Pasteur, HIV, Inflammation and 15 Persistence Unit, Paris, France; 5University of Alabama at Birmingham, Birmingham, AL 35294, 16 USA 17 18 *Corresponding author 19 R. Keith Reeves 20 Center for Virology and Vaccine Research 21 Beth Israel Deaconess Medical Center 22 3 Blackfan Circle 23 Boston, MA 02215 24 Ph: (617-735-4586) 25 Fax: (617-735-4527) 26 E-mail: [email protected] 27 28 †Current address: Committee on Immunology, University of Chicago, Chicago, IL 60637, USA 29 30 Running Title: Human Memory NK Cells 31 32 Abstract: 185 words 33 Main Text: 2713 words 34 Methods Text: 2035 words 35 5 Figures 36 7 Supplemental Figures 37 3 Supplemental Tables 38 62 references 39 40 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.09.374348; this version posted November 10, 2020.
    [Show full text]
  • Natural Killer Cell Memory in Infection, Inflammation and Cancer
    REVIEWS Natural killer cell memory in infection, inflammation and cancer Adelheid Cerwenka1 and Lewis L. Lanier2 Abstract | Immunological memory can be defined as a quantitatively and qualitatively enhanced immune response upon rechallenge. For natural killer (NK) cells, two main types of memory exist. First, similarly to T cells and B cells, NK cells can exert immunological memory after encounters with stimuli such as haptens or viruses, resulting in the generation of antigen-specific memory NK cells. Second, NK cells can remember inflammatory cytokine milieus that imprint long-lasting non-antigen-specific NK cell effector function. The basic concepts derived from studying NK cell memory provide new insights about innate immunity and could lead to novel strategies to improve treatments for infectious diseases and cancer. The ability to form immunological memory is tradi- We focus on the roles of memory NK cells in contact tionally considered as a hallmark of adaptive immu- hypersensitivity (CHS) responses, in viral infection and nity. However, increasing evidence suggests that innate in cancer, and we discuss the therapeutic potential of immune cells can also ‘remember’ prior exposures to targeting NK cells for improved treatments of infectious certain stimuli. Immunological memory, defined as diseases and cancer. responding qualitatively or quantitatively at a higher magnitude upon a secondary immune stimulation, has Identification of memory NK cells been demonstrated in invertebrates, as well as in innate In 2006, the observation that mice lacking T cells and immune cells in mammals. In invertebrates (from B cells could develop CHS responses to various distinct shellfish to worms and insects) recall responses against haptens introduced the concept that NK cells can mediate patho­gens have been described (see REF.
    [Show full text]
  • NK Cell-Based Immunotherapy for Hematological Malignancies
    Journal of Clinical Medicine Review NK Cell-Based Immunotherapy for Hematological Malignancies Simona Sivori 1,2, Raffaella Meazza 3 , Concetta Quintarelli 4,5, Simona Carlomagno 1, Mariella Della Chiesa 1,2, Michela Falco 6, Lorenzo Moretta 7, Franco Locatelli 4,8 and Daniela Pende 3,* 1 Department of Experimental Medicine, University of Genoa, 16132 Genoa, Italy; [email protected] (S.S); [email protected] (S.C.); [email protected] (M.D.C.) 2 Centre of Excellence for Biomedical Research, University of Genoa, 16132 Genoa, Italy 3 Department of Integrated Oncological Therapies, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy; raff[email protected] 4 Department of Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, 00165 Rome, Italy; [email protected] (C.Q.); [email protected] (F.L.) 5 Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy 6 Integrated Department of Services and Laboratories, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; [email protected] 7 Department of Immunology, IRCCS Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy; [email protected] 8 Department of Gynecology/Obstetrics and Pediatrics, Sapienza University, 00185 Rome, Italy * Correspondence: [email protected]; Tel.: +39-010-555-8220 Received: 20 September 2019; Accepted: 11 October 2019; Published: 16 October 2019 Abstract: Natural killer (NK) lymphocytes are an integral component of the innate immune system and represent important effector cells in cancer immunotherapy, particularly in the control of hematological malignancies. Refined knowledge of NK cellular and molecular biology has fueled the interest in NK cell-based antitumor therapies, and recent efforts have been made to exploit the high potential of these cells in clinical practice.
    [Show full text]
  • Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant
    Published OnlineFirst August 8, 2016; DOI: 10.1158/0008-5472.CAN-16-0839 Cancer Microenvironment and Immunology Research Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells Dhifaf Sarhan1, Frank Cichocki1, Bin Zhang2, Ashley Yingst3, Stephen R. Spellman4, Sarah Cooley1, Michael R. Verneris3, Bruce R. Blazar3, and Jeffrey S. Miller1 Abstract Human cytomegalovirus (CMV)-induced adaptive natural kill- blockade. Mechanistically, TIGIT signaling in NK cells after MDSC er (NK) cells display distinct phenotypic and functional charac- coculture led to a decrease in the phosphorylation of ZAP70/Syk teristics, including properties of immune memory. We hypothe- and ERK1/2. These effects were reversed by blocking TIGIT on NK sized that these cells may be more resistant to suppression cells or by inhibiting production of reactive oxygen species (ROS) mediated by immunoregulatory cell subsets, making them attrac- by MDSCs, the latter of which upregulated the TIGIT ligand tive for use in cancer therapy. Here we report that relative to CD155 on MDSCs. Accordingly, the blunted cytotoxicity of NK conventional NK cells, adaptive NK cells express lower levels of cells cocultured with MDSCs against tumor cells could be reversed the inhibitory receptor T-cell Ig and ITIM domain (TIGIT), which by blocking TIGIT or ROS production. Overall, our results results in resistance to immune suppression mediated by mye- show how adaptive NK cells arising in response to CMV infec- loid-derived suppressor cells (MDSC), as derived from cytokine tion can escape MDSC-mediated suppression, and defined induction in normal blood or patients with myelodysplastic TIGIT antagonists as a novel type of checkpoint inhibitor to syndrome.
    [Show full text]